03 June 2005
Immediate Release 3 June 2005
('VASTox' or 'the Company')
RESULT of AGM
Oxford, UK: 3 June 2005 - VASTox plc (AIM: VOX), the Oxford-based drug discovery
and services business focused on chemical genomics, is pleased to announce that
all of the resolutions at the AGM of the Company, held today, were duly passed.
Professor Stephen Davies, Non-Executive Chairman of Vastox, commented: 'Since
our successful flotation on AIM in October last year the Company has made
significant progress with its proprietary programmes in Duchenne Muscular
Dystrophy and Tuberculosis. Vastox has also signed several new service deals,
relocated to new facilities in Oxfordshire and strengthened its Scientific
Advisory Board in key areas of technology and drug development. The business is
in a strong position for future growth.'
VASTox 07766 913898
Steven Lee, Chief Executive Officer
Buchanan Communications 020 7466 5000
Tim Anderson / Mark Court / Mary-Jane Johnson
Notes for Editors:
VASTox is a chemical genomics technology company that both provides services to
the pharmaceutical industry, and discovers and develops proprietary novel drugs.
The company's technology platform aims to use high volume, high content
screening using zebrafish and fruitflies to provide a high level of
predictability of the efficacy and toxicity of potential drug compounds in
humans which has the potential to dramatically decrease the time and cost of
drug discovery and development. VASTox was formed in January 2003, from the
University of Oxford, by some of the UK's foremost scientists who have taken a
highly creative approach to the problems involved in drug discovery and who have
a proven record in delivering technological excellence. The company listed on
the London Stock Exchange AIM in October 2004.
This information is provided by RNS
The company news service from the London Stock Exchange